Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Mantle Cell Lymphoma Articles

KTE-X19 Poised to Have Promising Future in MCL Paradigm
David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.
Bendamustine Plus Rituximab Shows Promise as Induction Therapy in Mantle Cell Lymphoma
Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.
New BTK Inhibitor Expands Treatment Options for Patients With MCL
Javier Munoz, MD, MS, FACP, discusses zanubrutinib’s path to approval in mantle cell lymphoma and its future potential.
The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.
Rule Reflects on Continued Benefit With Ibrutinib in Relapsed/Refractory MCL
Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.
KTE-X19 MCL Application Enters EU Regulatory Pipeline
The European Medicines Agency has validated and is now evaluating a Marketing Authorization Application for the CAR T-cell therapy KTE-X19 for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.
Expert Highlights Advances in MCL and DLBCL
Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.
Wang Highlights Encouraging CAR T-Cell Activity in MCL
Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.
Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL
Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.
FDA Approval Sought for KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma
A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma. 
Publication Bottom Border
Border Publication
x